K. G. Houwelingen

Women treated with second‐generation zotarolimus‐eluting resolute stents and everolimus‐eluting xience V stents: insights from the gender‐stratified, randomized, controlled TWENTE trial

J. W. Louwerenburg, M. Stoel, F. H. Man, 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt–chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial

M. Stoel, A. Roguin, C. von Birgelen, 2018, The Lancet.

Comparison of frequency of periprocedural myocardial infarction in patients with and without diabetes mellitus to those with previously unknown but elevated glycated hemoglobin levels (from the TWENTE Trial).

J. W. Louwerenburg, M. Stoel, R. Stolk, 2012, The American journal of cardiology.

Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2013, Journal of the American College of Cardiology.

Unilateral and Multilateral Congenital Coronary‐Pulmonary Fistulas in Adults: Clinical Presentation, Diagnostic Modalities, and Management With a Brief Review of the Literature

R. Slart, R. Braam, S. Said, 2014, Clinical cardiology.

A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2012, Journal of the American College of Cardiology.

Micro-computed tomographic assessment following extremely oversized partial postdilatation of drug-eluting stents.

J. Feijen, C. von Birgelen, C. Birgelen, 2010 .

Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents 2-Year Follow-Up of the Randomized TWENTE Trial

M. Stoel, G. Linssen, C. Birgelen, 2013 .

Three contemporary thin‐strut drug‐eluting stents implanted in severely calcified coronary lesions of participants in a randomized all‐comers trial

M. Stoel, F. H. Man, C. von Birgelen, 2020, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Impact of previous coronary artery bypass surgery on clinical outcome after percutaneous interventions with second generation drug-eluting stents in TWENTE trial and non-enrolled TWENTE registry.

M. Stoel, C. von Birgelen, G. Linssen, 2014, International journal of cardiology.

Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and Xience V stents in the randomized TWENTE trial.

C. von Birgelen, G. Linssen, F. de Man, 2015, American heart journal.